Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) on Tuesday, plunged -0.37% from the previous trading day, before settling in for the closing price of $13.52. Within the past 52 weeks, ARWR’s price has moved between $9.57 and $30.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -2.87%. The company achieved an average annual earnings per share of 41.08%. With a float of $114.31 million, this company’s outstanding shares have now reached $125.57 million.
Let’s determine the extent of company efficiency that accounts for 609 employees. In terms of profitability, gross margin is -272.28%, operating margin of -25037.88%, and the pretax margin is -25870.12%.
Arrowhead Pharmaceuticals Inc (ARWR) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arrowhead Pharmaceuticals Inc is 16.75%, while institutional ownership is 70.88%. The most recent insider transaction that took place on Apr 11 ’25, was worth 583,692. In this transaction Chief Executive Officer of this company sold 50,800 shares at a rate of $11.49, taking the stock ownership to the 3,921,255 shares. Before that another transaction happened on Apr 10 ’25, when Company’s Chief Executive Officer sold 50,000 for $10.87, making the entire transaction worth $543,500. This insider now owns 3,972,055 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.08% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Arrowhead Pharmaceuticals Inc (ARWR) is currently performing well based on its current performance indicators. A quick ratio of 6.09 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 739.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.15, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -3.69 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Looking closely at Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR), its last 5-days average volume was 1.16 million, which is a drop from its year-to-date volume of 1.97 million. As of the previous 9 days, the stock’s Stochastic %D was 89.29%. Additionally, its Average True Range was 0.97.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 22.39%, which indicates a significant decrease from 90.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.99% in the past 14 days, which was higher than the 71.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.86, while its 200-day Moving Average is $20.02. However, in the short run, Arrowhead Pharmaceuticals Inc’s stock first resistance to watch stands at $13.77. Second resistance stands at $14.06. The third major resistance level sits at $14.30. If the price goes on to break the first support level at $13.23, it is likely to go to the next support level at $12.99. Now, if the price goes above the second support level, the third support stands at $12.70.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
Market capitalization of the company is 1.85 billion based on 137,317K outstanding shares. Right now, sales total 3,550 K and income totals -599,490 K. The company made 2,500 K in profit during its latest quarter, and -173,090 K in sales during its previous quarter.
